EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Alpha-radioimmunotherapy of B-cell non Hodgkins lymphoma Preclinical evaluation of 213Bi-labeled CD19- and CD20-CHX-A-DTPA conjugates



Alpha-radioimmunotherapy of B-cell non Hodgkins lymphoma Preclinical evaluation of 213Bi-labeled CD19- and CD20-CHX-A-DTPA conjugates



Onkologie 23(Sonderheft 7): 47, October




(PDF emailed within 1 workday: $29.90)

Accession: 034377785

Download citation: RISBibTeXText



Related references

Alpha-radioimmunotherapy of B-lineage non-hodgkins lymphoma using 213Bi-labelled anti-CD19- and anti-CD20-CHX-A-DTPA. Abstracts of Papers American Chemical Society 225(1-2): NUCL 78, 2003

Alpha-radioimmunotherapy with 213Bi-labelled CD19, CD20 and CD22 antibodies for B-cell lymphoma. Blood 92(10 SUPPL 1 PART 1-2): 416A, Nov 15, 1998

Treatment of B-lineage non-Hodgkins lymphoma using a 213Bi-labeled anti-CD20-CHX-A-DTPA antibody conjugate. Journal of Nuclear Medicine 43(5 Supplement): 116P, 2002

High-dose, myeloablative radioimmunotherapy of mantle cell non-Hodgkins lymphoma with the 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support Results of a pilot study. Cancer Biotherapy & Radiopharmaceuticals 15(4): 408, 2000

Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody in relapsed non-Hodgkins lymphoma Dosimetry and radioimmunotherapy. Journal of Nuclear Medicine 41(5 Suppl ): 268P, 2000

Preclinical studies on yttrium-90-labeled CDR-grafted monoclonal antibody for radioimmunotherapy of non-Hodgkins lymphoma. Journal of Nuclear Medicine 39(5 SUPPL ): 105P, 1998

The use of neuraminidase to increase the density of b lineage specific antigens cd19 and cd20 on b non hodgkins lymphoma cell lines. 1987

Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 16(1): 60-66, 2002

Impact of metabolic and pharmacokinetic variability on dosing methodology for radioimmunotherapy in patients with CD20+ B-cell non-Hodgkins lymphoma. Journal of Nuclear Medicine 44(5 Supplement): 415P, 2003

Radioimmunotherapy of low-grade B-cell lymphoma with ( 90)Y-labeled anti-CD20 monoclonal antibody (Zevalin). Nihon Hoshasen Gijutsu Gakkai Zasshi 65(3): 367-371, 2009

Radioimmunotherapy of non hodgkins lymphoma with iodine 131 labeled anti pan b cell antibodies. Journal of Nuclear Medicine 30(5 SUPPL): 828, 1989

High-dose radioimmunotherapy/chemotherapy and autologous stem cell transplantation for poor risk and relapsed CD20+ non-Hodgkins lymphoma Early feasibility report. Blood 96(11 Part 2): 374b-375b, November 16, 2000

Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. International Journal of Oncology 15(5): 1017-1025, 1999

High-dose radioimmunotherapy of mantle cell lymphoma with the 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Journal of Nuclear Medicine 42(5 Supplement): 156P-157P, 2001

Pretarget radioimmunotherapy with anti-CD20 fusion protein in patients with non-Hodgkins lymphoma. Journal of Nuclear Medicine 43(5 Supplement): 116P-117P, 2002